Description
Cagrilintide is a synthetic analog of amylin, a 37-amino-acid peptide hormone naturally co-secreted with insulin from pancreatic beta cells. It was designed as a long-acting version of native amylin, with specific amino acid substitutions and an acylation, the attachment of a fatty acid chain, that slows clearance from solution.
Cagrilintide’s primary research interest comes from its role in combination weight-loss research. Amylin works as a satiety signal alongside insulin, slowing gastric emptying and reducing food intake through a mechanism distinct from GLP-1 receptor agonists like semaglutide. Novo Nordisk has studied cagrilintide combined with semaglutide, under the investigational name CagriSema, in Phase 3 trials, with published data showing meaningfully greater weight loss than semaglutide alone in trial populations, on the premise that combining an amylin agonist with a GLP-1 agonist targets complementary appetite-regulation pathways.
The compound has the molecular formula C194H312N54O59S2, molecular weight approximately 4,409 g/mol, CAS 1415456-99-3, classified as an acylated amylin receptor agonist. The fatty acid sidechain enables albumin binding and extends the molecule’s half-life substantially compared to native amylin, which breaks down within minutes in solution. This product is strictly for research purposes only.
PubChem Reference: View compound profile on NIH PubChem
Key Characteristics
MOLECULAR PROFILE
Formula: C194H312N54O59S2
Weight: 4,409 g/mol
CAS: 1415456-99-3
Structure: Modified amylin analog
PHYSICAL PROPERTIES
Form: White lyophilized powder
Solubility: Soluble in water
Half-life: Extended compared to native amylin
Storage: Keep refrigerated 36‑46 °F (2‑8 °C)
Cagrilintide in Published Research
Because Novo Nordisk has advanced cagrilintide through registered Phase 3 trials as part of CagriSema, more clinical trial data exists for this compound than for most research peptides in the metabolic category. Trial results have reported additive weight loss when combined with semaglutide compared to semaglutide monotherapy, along with research into amylin agonism’s role in slowing gastric emptying and modulating central satiety signaling independent of the GLP-1 pathway.
Frequently Asked Questions :
What is Cagrilintide studied for?
Amylin receptor agonism for appetite regulation and weight loss, most often studied in combination with GLP-1 agonists like semaglutide.
What does the CagriSema trial data show?
Phase 3 data reports greater weight loss with the cagrilintide/semaglutide combination than semaglutide alone in trial populations.
How does it differ from Tirzepatide?
Different mechanism, amylin receptor agonism vs. GIP/GLP-1 dual agonism, both studied for weight loss through different pathways.
How should it be reconstituted and stored?
Bacteriostatic water, refrigerate 2–8°C.Where can I buy it? 5mg and 10mg kits, HPLC/MS verified, not the branded combination product.
Prof. Gregory S. Whitman –
A superior synthetic amylin analog. The specific amino acid substitutions reduce aggregation compared to native peptide. My postdocs noted reproducible results in replicate experiments highly
Dr. Fatima Z. El-Sayed –
Very effective in our in vivo pharmacokinetic trials. The long duration of action allowed for once-daily dosing in animal models. Shipping was prompt and lyophilized powder arrived intact
Prof. David K. Murakami –
Perfectly matched the published molecular weight of 4.3 kDa via MALDI-TOF. Solubility in alkaline buffer was excellent. Reliable supplier for long-acting peptide studies
Dr. Rebecca T. Lawson –
Exceptional purity and consistency across multiple batches. The fatty acid acylation delivers the expected extended half-life in our rodent models. Gold standard for amylin analog research in my lab
Dr. Anita K. Patel –
Good value for the price range ($110–$168). Activity in receptor binding assays matched literature values within 5%. Would appreciate slightly faster dry ice shipment, but overall excellent product
Prof. Lars E. Johansson –
Flawless performance in both cell-based and biochemical assays. The C194H312N62O50S7 composition was verified by our lab’s elemental analysis. Already placed a repeat order for our metabolic research cohort